OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab

Core Insights - OSE Immunotherapeutics announced that over 90% of ulcerative colitis patients who responded to Lusvertikimab maintained symptomatic remission for an additional 24 weeks [2][4][15] - The open-label extension of the Phase 2 CoTikiS study demonstrated a significant improvement in remission rates, with 61% of previously non-responding participants achieving remission after further treatment [3][5][15] - Lusvertikimab showed a favorable safety profile throughout the study, with no increased rates of infection reported [4][15] Summary by Sections Study Findings - The Phase 2 CoTikiS study's open-label extension revealed that 89% of participants continued into the extension period, and 87% completed it [4][9] - Symptomatic remission rates improved across all dose groups during the extension period, indicating a deepening of treatment efficacy [5][9] - Participants receiving the 850 mg dose showed plateaued remission rates after Week 14, while those on the 450 mg dose continued to improve through Week 34 [9][15] Clinical Implications - The findings suggest Lusvertikimab's potential as a monotherapy for ulcerative colitis, addressing a significant unmet need in symptom management and patient quality of life [5][6] - The study results challenge the typical therapeutic ceiling, where only 25-30% of patients achieve and maintain remission with existing treatments [5][6] Future Development - The complete CoTikiS results bolster confidence in Lusvertikimab's novel mechanism of action and its potential application in other chronic autoimmune and inflammatory diseases [6][8] - The study supports the progression of Lusvertikimab's development towards a long-acting therapy aimed at treating underlying disease pathophysiology [6][8]